HOME >> MEDICINE >> NEWS
Second-generation antipsychotic medications appear to offer little advantage over older drugs

Among patients with schizophrenia whose medication is changed because of ineffectiveness or harmful side effects, second-generation antipsychotic drugs do not appear to offer significant benefits compared to first-generation antipsychotic drugs, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals. The findings run contrary to the widely held perception that second-generation antipsychotic agents are safer and more effective in treating patients with schizophrenia than the less-expensive first-generation class of medications.

For almost 50 years, antipsychotic medications have been the primary method of treating schizophrenia, a psychiatric disorder that causes a disconnect from reality and severe disturbances in thought, mood and behavior. Patients taking first-generation antipsychotics--so called because they were developed first--often relapse or develop severe side effects, including sedation (feeling tranquilized) and involuntary muscle movements, according to background information in the article. The development of second-generation antipsychotics was thought to be a major advance primarily because the drugs reduced such side effects. Claims that second-generation drugs are more effective than first-generation drugs have shifted treatment patterns away from first-generation medications, although research comparing the drug classes has had mixed results.

Peter B. Jones, M.D., Ph.D., University of Cambridge and Cambridgeshire and Peterborough Mental Health NHS Trust, Cambridge, England, and colleagues studied 227 individuals age 18 to 65 with schizophrenia. "The key question was whether the additional acquisition costs of second-generation antipsychotics over first-generation antipsychotics would be offset by improvements in health-related quality of life or savings in the use of other health and social care services in people with schizophrenia for whom a change in drug trea
'"/>

Contact: Peter B. Jones, M.D., Ph.D.
pbj21@cam.ac.uk
JAMA and Archives Journals
2-Oct-2006


Page: 1 2 3 4

Related medicine news :

1. USC-led study suggests little benefit from antipsychotics in Alzheimers
2. Most effective antipsychotic drug has serious health consequences
3. Number of children and teens treated with antipsychotics increases sharply
4. Atypical antipsychotic drugs for dementia may be associated with small increased risk of death
5. NIMH study finds antipsychotic Risperidone safe, effective as intermediate term treatment for autism
6. Metabolic side effects of antipsychotics are known, but rarely monitored
7. Different antipsychotic medications may have different effects on brain volume
8. Study shows new antipsychotic drug prevents brain loss in schizophrenia
9. Commonly used pain medications do not prevent Alzheimers disease
10. Standard long-acting insulin as good as newer medications
11. MS patients not receiving medications to slow disease progression, research shows

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like coming home. Life-long ... of Geneva. During his first days on the job, he’s run into residents of ... and I like knowing that they’re living in such a wonderful place,” he said. ...
(Date:8/31/2015)... Riviera Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Wilander to their growing list of major sports figures who are finding joint pain ... Slam titles, and former #1 men’s tennis player in the world said, “For the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... the Talent Management Division , a department devoted to helping organizations identify ... Talent management goes beyond selection, and The Brooks Group believes in offering a ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... networking and relationship-marketing firm, announced today the nominees vying for the 2015 ... U.S. Region. Executives include top-ranking decision makers representing national to global organizations ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted ... Owners and provided a tour of their North American facility following the S.M.A.R.T ... international companies expanding business in the U.S. , The PartnerTech Inc. North ...
Breaking Medicine News(10 mins):Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:PartnerTech Supports Economic Growth as Host 2
(Date:8/31/2015)... , Aug. 31, 2015  QT Vascular Ltd., together ... and together with its subsidiaries, the "Group"), a ... distribution of advanced therapeutic solutions for the minimally ... final results of the below-the-knee ("BTK") cohort of ... which were presented on August 15, 2015 at ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
Cached News: